UroGen Pharma Ltd. reiterated earnings guidance for the full year 2023. For the year, company expects net product revenues from JELMYTO to be in the range of $76 million to $86 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.06 USD | -2.94% | -9.10% | -12.73% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.73% | 459M | |
+3.72% | 106B | |
+7.02% | 23.47B | |
-14.53% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.93% | 16.78B | |
+5.65% | 14.41B | |
+35.85% | 12.86B | |
+324.96% | 8.78B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023